*In some patients with continued daily use. One drop in each eye, twice daily (approximately 12 hours apart).
3
†
XiidraisanLFA-1antagonistforthetreatmentofdryeyedisease.Pivotaltrialdata:ThesafetyandefficacyofXiidrawereassessedinfour
12-week,randomized,multicenter,double-masked,vehicle-controlledstudies(N=2133).Patientsweredosedtwicedaily.Useofartificial
tearswasnotallowedduringthestudies.Thestudyendpointsincludedassessmentofsigns(basedonInferiorfluoresceinCornealStaining
Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100).
3
A larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at
2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials. Effects on signs of dry eye disease ICSS (on a scale from 0-4;
0=no staining; 4=coalescent) was recorded at each study visit. At day 84, a larger reduction in inferior corneal staining favoring Xiidra was
observed in 3 of the 4 studies.
3
Indication
Xiidra
®
(lifitegrastophthalmicsolution)5%isindicatedforthetreatmentofsignsandsymptomsofdryeyedisease(DED).
Important Safety Information
• Xiidraiscontraindicatedinpatientswithknownhypersensitivitytolifitegrastortoanyoftheotheringredients.
Not an actual patient.
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080